PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15687024

NIH pre-clinical screening program: overview and current status.

Angelo Izzo·Lise Brandt·Todd Lasco·Anna-Paula Kipnis·Ian Orme
View original source ↗Export metadata ↓

Abstract

The increase in the number of cases of Mycobacterium tuberculosis around the world has lead to a greater need for a more efficacious vaccine than the currently used M. bovis BCG. Despite the relative success of this attenuated vaccine there are multiple examples where alternative strategies are desperately needed. In 1996, the National Institutes of Health published a request calling for applications to test newly developed vaccines against tuberculosis. The current screening program at Colorado State University has tested a wide range of novel vaccine candidates.

Explore related subjects

Adjuvants, ImmunologicAnimalsBCG VaccineDisease Models, AnimalDrug Evaluation, PreclinicalGuinea PigsHumansMiceNational Institutes of Health (U.S.)TuberculosisTuberculosis VaccinesUnited StatesVaccines, AttenuatedVaccines, DNAJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Angelo Izzo, Lise Brandt, Todd Lasco, Anna-Paula Kipnis, Ian Orme. 2005-01-17. NIH pre-clinical screening program: overview and current status.. https://doi.org/10.1016/j.tube.2004.09.008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine.

Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm) is a synthetic peptide known to activate human neutrophils, monocytes and dendritic cells, resulting in the enhancement of superoxide generation, bactericidal activity, chemotactic migration and survival. In this study, we demonstrated that WKYMVm enhanced the surface expression of CD80, but not that of CD40, CD86 and MHC class II, on mouse bone marrow-derived dendritic cells which is one of the essential costimulatory signals for the induction of immune responses. Furthermore, when WKYMVm was codelivered with HIV, HBV and Influenza DNA vaccines, WKYMVm selectively enhanced the vaccine-induced CD8(+) T cell responses in a dose-dependent manner, in terms of IFN-gamma secretion and cytolytic activity. Our results indicate that a synthetic peptide, WKYMVm can function as a novel adjuvant for DNA vaccine.

Adjuvants, Immunologic↗
PubMed2005

CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs.

This study evaluated the adjuvant activity of a porcine-specific type A CpG-containing oligodeoxynucleotide (CpG-ODN) in a DNA-vaccine against Pseudorabies virus (PrV) infection. This vaccine, composed of three independent plasmids encoding PrV gB, gC and gD glycoproteins, was injected alone or was co-injected with CpG-ODN or control GpC-ODN. CpG-ODN improved the PrV-specific humoral immune response and provided better clinical protection against lethal PrV-infection. The PrV-specific cell-mediated immune response seemed also to be increased.

Adjuvants, Immunologic↗
PubMed2005

Synergism between active listeriolysin O and dimethyldioctadecylammonium bromide to activate CD8(+) T cells.

Purified recombinant listeriolysin O (LLO) was assessed for its ability to induce T cell responses in mice. Intraperitoneal immunisation with LLO, as a fusion with glutathione-S-transferase (GST), induced the production of LLO-specific CD8(+) T cells, but not LLO-specific CD4(+) T cells. The generation of this response could be blocked by pre-treatment with cholesterol, indicating a requirement for LLO pore formation. An increase in the LLO-specific response of both CD8(+) and CD4(+) T cells could be detected following the addition of dimethyldioctadecylammonium bromide (DDA), although the generation of this response was not dependent upon LLO pore formation, suggesting that DDA might change the presentation pathway of LLO leading to activation of the CD8(+) T cells. However, this response was dependent upon the presence of structurally intact LLO, suggesting a requirement for the innate recognition of LLO in the activation of the CD4(+) and CD8(+) T cells. Therefore, DDA and LLO can act synergistically to induce the production of a CD8(+) T cell response.

Adjuvants, Immunologic↗